Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes

Inclusion Criteria:

- Informed consent obtained before any trial-related activities. (Trial-related
activities are any procedure that would not have been performed during normal
management of the subject.)

- Insulin naïve type 2 diabetes subjects (as diagnosed clinically) for at least 3
months (no previous insulin treatment or previous short term insulin treatment
maximeum 14 days within the last 3 months)

- Treatment with one or two oral anti-diabetic drug (OADs): metformin, sulphonylurea
(SU) (or other insulin secretagogue e.g. repaglinide, nateglinide), alpha-glucosidase
inhibitors for at least 2 months at a stable maximally tolerated dose or at least
half maximally allowed dose according to the summary of product characteristics (SPC)
or locally approved PI

- HbA1c 7.0-11.0 % (both inclusive)

- Body Mass Index (BMI) 23-42 kg/m^2 [lb/in^2 x 703] (both inclusive)

Exclusion Criteria:

- Metformin contraindication according to local practice

- Thiazolidinedione (TZD) treatment within previous three months prior to visit 1

- Any systemic treatment with products which in the Investigator's opinion could
interfere with glucose or lipid metabolism (e.g. systemic corticosteroids) three
months prior to randomisation

- Subject has a clinically significant, active (during the past 12 months) disease of
the gastrointestinal, pulmonary, neurological, genitourinary, or haematological
system (except for conditions associated with type 2 diabetes) that, in the opinion
of the Investigator, may confound the results of the trial or pose additional risk in
administering trial drug